Major depression and the synthetic enhancer substances, (−)-deprenyl and R-(−)-1-(benzofuran-2-yl)-2-propylaminopentane

@article{Gaszner2006MajorDA,
  title={Major depression and the synthetic enhancer substances, (−)-deprenyl and R-(−)-1-(benzofuran-2-yl)-2-propylaminopentane},
  author={P. Gaszner and I. Miklya},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2006},
  volume={30},
  pages={5-14}
}
  • P. Gaszner, I. Miklya
  • Published 2006
  • Medicine, Psychology
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • Because of the high number of therapy-resistant depressions and the growing number of suicides, there is still a great need for the development of antidepressants with a new pharmacological spectrum. The finding that phenylethylamine and tryptamine are endogenous enhancers of the impulse propagation mediated release of catecholamines and serotonin in the brain, and the development of synthetic enhancer substances opened the possibility to stimulate catecholaminergic and serotonergic neurons in… CONTINUE READING
    11 Citations
    Neuroprotective and Antioxidant Effects of Novel Benzofuran-2-Carboxamide Derivatives
    • 8
    • PDF
    Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma
    Trace amine-associated receptor 1-Family archetype or iconoclast?
    • D. Grandy
    • Biology, Medicine
    • Pharmacology & therapeutics
    • 2007
    • 150
    Antidepressants for smoking cessation.
    • 228

    References

    SHOWING 1-10 OF 47 REFERENCES
    (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
    • J. Knoll
    • Medicine, Chemistry
    • Pharmacology & toxicology
    • 1998
    • 70
    The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant.
    • 20
    The possible mechanisms of action of (-)deprenyl in Parkinson's disease
    • J. Knoll
    • Psychology, Medicine
    • Journal of Neural Transmission
    • 2005
    • 57
    Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    • J. Knoll
    • Biology, Medicine
    • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
    • 1995
    • 26
    R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    • J. Knoll
    • Biology, Medicine
    • Journal of neural transmission. Supplementum
    • 1987
    • 109